Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | QDPR | P09417 | 3/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30745981 | 0.87 | HTR2C (0.54) | HTR2CSIGMAR1QDPRHTR6NAMPT | |
| SCHEMBL14684840 | 0.82 | HTR2C (0.59) | HTR2CSIGMAR1QDPRNAMPTHTR2A | |
| SCHEMBL3986448 | 0.81 | HTR2C (0.54) | HTR2CSIGMAR1QDPRNAMPT | |
| Hydrochloric Acid SCHEMBL5662417 | 0.80 | HTR2C (0.55) | HTR2CSIGMAR1QDPRNAMPT | |
| SCHEMBL30431801 | 0.79 | HTR2C (0.66) | HTR2CSIGMAR1QDPRHTR6HTR7 | |
| SCHEMBL4790435 | 0.79 | HTR2C (0.66) | HTR2CSIGMAR1QDPRHTR6HTR7 | |
| SCHEMBL4767836 | 0.78 | HTR2C (0.50) | HTR2CSIGMAR1QDPRNAMPTCTSL | |
| Hydrochloric Acid SCHEMBL9311920 | 0.78 | HTR2C (0.67) | HTR2CSIGMAR1QDPRHTR6HTR7 | |
| SCHEMBL4791120 | 0.77 | SIGMAR1 (0.79) | HTR2CSIGMAR1QDPRHTR6HTR7 | |
| Hydrochloric Acid SCHEMBL4793458 | 0.76 | HTR2C (0.79) | HTR2CSIGMAR1QDPRHTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2020132561-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | ERG28, CYP51A1, MANBA | HTR2C 4135/4885SIGMAR1 2840/4885QDPR 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.